Why Galecto (GLTO) Shares Are Down 27% Today
Why Galecto (GLTO) Shares Are Down 27% Today
In exchange for the rights to BRM-1420, Galecto issued shares representing 4.99% of its outstanding common stock to Bridge Medicines, along with preferred shares that could convert to an additional 12.8% of common stock upon stockholder approval. Galecto Inc (NASDAQ:GLTO) shares are trading lower by 27% to $8.50 during Monday's session. The company issued 62,594 shares of common stock and 160,562 of preferred convertible shares to Bridge Medicine as part of their acquisition for the rights to BRM-1420.
Galecto公司（纳斯达克股票代码：GLTO）股价在周一交易时下跌了27%，跌至8.50美元。该公司发行了62,594股普通股和160,562股可转换优先股给Bridge Medicine，作为其收购BRm-1420权利的一部分。
What Happened: Galecto announced a strategic shift to focus on cancer and liver disease, particularly leveraging its clinical-stage asset GB1211, which the company says has shown positive results in non-small cell lung cancer (NSCLC) and cirrhosis studies.
事件经过：Galecto宣布战略转变，专注于癌症和肝病，特别是利用其临床阶段资产GB1211，该公司表示已在非小细胞肺癌（NSCLC）和肝硬化研究中显示出积极结果。
To strengthen its pipeline, Galecto has acquired global rights to BRM-1420, a novel drug developed by Bridge Medicines, a company co-founded by Takeda. Galecto says BRM-1420 has shown promise in treating genetic subsets of acute myeloid leukemia (AML) and could enhance standard therapies.
为加强其产品线，Galecto已获得了Bridge Medicines开发的新药BRm-1420的全球权利，这是Takeda共同创立的一家公司。Galecto表示，BRm-1420在治疗急性骨髓性白血病（AML）的遗传亚组方面表现出潜力，并可能增强标准疗法。
In exchange for the rights to BRM-1420, Galecto issued shares representing 4.99% of its outstanding common stock to Bridge Medicines, along with preferred shares that could convert to an additional 12.8% of common stock upon stockholder approval.
作为对BRm-1420权利的交换，Galecto发行了代表其未来普通股4.99%的股份给Bridge Medicines，并发行可转换为普通股额外12.8%的优先股，需股东批准。
Matthew Kronmiller, CEO of Bridge Medicines, will join Galecto as Executive Vice President of Strategy and Chief Business Officer. The transaction was approved by both companies' boards, with Leerink Partners advising Galecto and Lazard advising Bridge Medicines.
Matthew Kronmiller，Bridge Medicines的首席执行官，将加入Galecto担任战略与业务首席副总裁。交易获得了双方董事会的批准，Leerink Partners为Galecto提供建议，Lazard为Bridge Medicines提供建议。
Read Also: S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
阅读更多：标普500指数12个月内可能达到6300点，高盛表示，受到“强劲人工智能需求”和“利润扩张”的驱动。
How To Buy GLTO Stock
如何购买GLTO股票
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
除了手动到经纪所平台购买股票或者部分股票，您还可以通过购买持有股票的ETF，或者在401(k)中分配资金进入一项该类基金或其他工具的策略来获得股票的份额。例如，Coinbase属于金融部门。ETF通常持有许多能跟踪该部门的流动性和大型公司的股票，使投资者能够获得该股票板块内的趋势。
For example, in Galecto's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
举例来说，对于galecto的情况，它属于医疗保健板块。一个etf可能会持有许多流通性强、规模大的公司股票，帮助跟踪该板块，使投资者能够接触到该板块内的趋势。
According to data from Benzinga Pro, GLTO has a 52-week high of $23.50 and a 52-week low of $8.45.
根据Benzinga Pro的数据，GLTO的52周最高价为23.50美元，52周最低价为8.45美元。